Key points from article :
Radar Therapeutics develops “smart” mRNA medicines using RNA sensors.
The company recently raised $13.4 million to advance its internal programs and expand its team.
These sensors enable timely delivery of therapeutic payloads directly to the cells, with minimal systemic toxic side-effects.
This technology has the potential to enable a new generation of mRNA therapeutics.
RADAR platform can read the RNA profile of a cell and find cellular signatures that indicate disease, misbehavior and even aging.
Radar Therapeutics leverages advances in single-cell transcriptomic data to design “smart” mRNA therapies.
“With Radar’s technology, we can now precisely alter the biology of the cell, delete harmful cells, or potentially reprogram cells for autoimmune diseases,” said Jim Collins, co-founder of Radar.
